GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
March 09 2023 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
clinical-stage biotechnology company developing immunotherapies and
vaccines against cancer and infectious diseases, announced today
that it will report 2022 financial results on Thursday, March 23,
2023 after the market closes.
Following the release, management will host a live conference
call and webcast to provide a general business update and discuss
financial results. Subsequent to management’s prepared remarks,
there will be a Q&A period for analysts and others.
Thursday, March 23, 2023, 4:30 PM
ETDomestic:
877-269-7756International:
201-689-7817Conference ID:
13736454Webcast:
GeoVax
2022 Earnings Webcast
A webcast replay of the call will be available via
the same link as the live webcast approximately one hour after the
end of the call through June 23, 2023.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and
vaccines for cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in two
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
COVID-19 vaccine for immunocompromised patients such as those
suffering from hematologic cancers and other patient populations
for whom the current authorized COVID-19 vaccines are insufficient.
In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating
the vaccine as a more robust, durable COVID-19 booster among
healthy patients who previously received the mRNA vaccines. GeoVax
has a leadership team who have driven significant value creation
across multiple life science companies over the past several
decades. For more information, visit our
website: www.geovax.com.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024